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ORIGINAL ARTICLE
TERC polymorphisms are associated both with
susceptibility to colorectal cancer and with
longer telomeres
A M Jones,1 A D Beggs,1 L Carvajal-Carmona,1 S Farrington,2 A Tenesa,2 M Walker,2
K Howarth,1 S Ballereau,2 S V Hodgson,3 A Zauber,4 M Bertagnolli,5 R Midgley,6
H Campbell,7 D Kerr,6 M G Dunlop,2 I P M Tomlinson1
ABSTRACT
Background and aims Shorter telomeres have been
associated with increased risk of malignancy, including
colorectal cancer (CRC). Telomere length is heritable and
may be an intermediate phenotype linked to genetic
susceptibility to CRC.
Methods In a large sample, the study investigated
whether candidate single nucleotide polymorphisms
(SNP) in ‘telomere biology’ genes were associated with
telomere length in leucocytes. SNP associated with an
increased risk of CRC were searched for separately.
Results Carriers of the common allele at SNP
rs10936599, near the telomerase RNA component (TERC)
locus, had significantly longer telomeres. It was
independently found that the same rs10936599 allele
was associated with increased risk of both CRC and
colorectal adenomas. Neither telomere length nor CRC
risk was associated with variation near telomerase
reverse transcriptase or other telomere biology genes. In
silico analysis showed that SNP rs2293607 was strongly
correlated with rs10936599, mapped within TERC
transcripts, had a predicted effect on messenger RNA
folding and lay at a reported transcription factor binding
site. TERC mRNA were expressed, differing only at the
alleles of rs2293607, in CRC cell line HCT116. The long-
telomere/CRC-risk allele was associated with higher levels
of TERC mRNA and the formation of longer telomeres.
Conclusions Common genetic variation at TERC is
associated with both longer telomeres and an increased
risk of CRC, a potential mechanism being reduced levels
of cell senescence or death. This finding is somewhat
paradoxical, given retrospective studies reporting that
CRC cases have shorter telomeres than controls. One
possibility is that that association actually results from
poorer survival in patients with longer telomeres.
Chromosome telomeres consist of multiple short
repeats (TTTAGG) that protect against large-scale
genetic rearrangements. In most somatic cells,
telomeres shorten with cell divisions, eventually
leading to cellular senescence. Telomere length
decreases as humans age,1 and exceptionally long-
lived individuals have relatively long telomeres.2
Some patients have inherited tendencies to short
telomeres, resulting in diseases that include
dyskeratosis congenita,3 idiopathic pulmonary
ﬁbrosis4 and aplastic anaemia.5 6
In some human cells, including stem cells, telo-
mere length is maintained by the expression of the
telomerase enzyme.7 8 The holoenzyme’s core
activity is provided by telomerase reverse tran-
scriptase (TERT), which utilises the telomerase
RNA component (TERC) as a template to add
repeats to the existing telomeres. A hallmark of
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Significance of this study
What is already known about this subject?
< In retrospective, studies, shorter telomeres have
been found to be markers of, or causative for,
colorectal cancer (CRC) risk.
< We have found a number of common inherited
polymorphisms to be associated with CRC risk.
< Polymorphisms near the telomerase reverse
transcriptase (TERC) gene have been associated
with telomere length.
What are the new findings?
< The major allele at polymorphism rs10936599 is
associated with an increased risk of colorectal
carcinomas and adenomas, but is also
associated with longer telomeres.
< rs10936599 is strongly correlated with another
polymorphism, rs2293607, within the TERC
gene.
< TERC mRNA that differ only by the alleles at
rs2293607 have different expression levels and
the major allele causes longer telomeres in vitro,
as predicted by the genetic association data.
< There therefore exists a paradox in that TERC
polymorphisms have confirmed associations
with both CRC and longer telomeres, yet
shorter telomeres have classically been
associated with cancer risk.
How might it impact on clinical practice in the
foreseeable future?
< Constitutionally longer telomeres may predis-
pose to CRC.
< The relationship between shorter telomere
length and CRC risk is in doubt.
< It is possible that the reported relationship may
result from effects on prognosis rather than
susceptibility.
< CRC risk prediction using genetic data may be
more reliable under some circumstances than
reliance on intermediate biomarkers.
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cancer is a continuing ability to proliferate and/or avoid death.
Somatic activation of telomerase helps to confer these features
in many tumour types. In cervical cancer, for example, it has
been proposed that telomerase expression relies on high levels of
TERC that result from the ampliﬁcation of chromosome
3q26.2.9
Telomere length is a heritable trait,10e12 and a small number
of polymorphisms have been associated with telomere
length.13 14 The hypothesis that shorter telomeres predispose to
cancer in the general population initially gained support from an
increased risk of cancer15e18 in some of the diseases associated
with very short telomeres (see above), presumably as a conse-
quence of ‘chromosomal instability ’. Several studies have since
reported that leucocyte telomeres are shorter in cancer cases
than in controls,1 19e24 although the data are inconsistent
among studies and tumour types. Previous studies on colorectal
cancer (CRC) have produced conﬂicting results regarding asso-
ciations between leucocyte telomere length and CRC risk.
Prospective studies24e27 have found no convincing association
between telomere length and CRC risk (see supplementary
table 1, available online only). In contrast, the retrospective arm
of the study of Pooley et al26 found a strong association between
shorter telomeres and CRC risk (N¼2249 cases and 2161
controls, ORquartile1v4 2.14, 95% CI 1.77 to 2.59). Together with
the same authors’ prospective data, this ﬁnding raises the
possibility that the retrospective association reﬂected not disease
risk, but effects of the cancer itself and/or anticancer therapies
and/or effects of telomere length on survival.
In order to acquire sufﬁcient samples to empower analysis,
studies have examined telomere length in leucocytes and no
study has examined telomeres in the colorectum with regard to
CRC risk. O’Sullivan et al1 and Risques et al28 measured telo-
meres in normal colonocytes in a relatively small sample set;
they found not only the expected telomere shortening with age,
but also some evidence of longer telomeres in the oldest indi-
viduals in the study. However, other studies on normal colonic
mucosa from CRC patients have failed to ﬁnd this biphasic
relationship.29 30 O’Sullivan et al1 and Risques et al28 did not
relate colonocyte telomere length to that in leucocytes.
We have searched for associations between variants in telomere
pathway genes and telomere length in leucocytes. We have
related the ﬁndings to data from the same samples, obtained as
part of a genome-wide association study of CRC predisposition.31
The results demonstrate the existence of an association between
telomere length and CRC predisposition, but show that this
association is more complex than previously suspected.
METHODS
Study participants
Three sets of samples were taken from the general population or
from individuals without a cancer history31: (1) 2489 population
controls (mean age 44 years, 49% men) from the Wellcome Trust
CaseeControl Consortium 2 National Blood Service (NBS)
cohort (http://www.wtccc.org/; (2) 968 subjects (mean age
51 years, 52% men) from the Scottish population for the COGS
study; and (3) 455 UK CORGI study controls (mean age
58 years, 41% men), these being individuals with a spouse or
partner with CRC, but themselves unaffected by cancer and
without a family history (to second degree relative level) of
colorectal neoplasia.
CRC patients were from three sources:31 (1) 717 cases (mean
age 67 years, 64% men) from the VICTOR study, a phase III,
randomised controlled trial of rofecoxib after potentially cura-
tive therapy; (2) 888 early-onset (age #55 years) Scottish cases
(mean age 49 years, 51% men) from COGS; and (3) 552 familial
CRC cases (mean age 63 years, 48% men) from CORGI. For
VICTOR, 51% of CRC were stage II, all the remainder being
stage III; 62% of VICTOR cases received 5-ﬂuorouracil-based
chemotherapy and 8.3% had radiotherapy. Blood samples were
taken a median of 127 weeks after surgery (interquartile range
100e170). For COGS, 19% of cancers were stage I, 31% stage II,
32% stage III and 18% stage IV; 28% of COGS patients received
chemotherapy and 8% radiotherapy, and blood was sampled
a median of 20 weeks after diagnosis (interquartile range
12e33). As CORGI samples were collected from cancer genetics
clinics, they were highly variable in terms of their sampling
dates post-diagnosis; data on cancer stage and chemotherapy
were similarly variable in terms of their availability.
For studies of genetic susceptibility to CRC only, we addi-
tionally analysed 496 cases (mean age 62 years, 59% men) from
the QUASAR2 study of adjuvant capecitabine with or without
bevacizumab in stage II/III CRC. We excluded QUASAR2
samples from the telomere length studies, because blood was
generally taken from these patients during the period of
chemotherapy, potentially leading to considerable confounding
effects from neutropaenia and other relative or absolute changes
in the leucocyte count.
A total of 1569 individuals of white European ancestry with
multiple (two to 10) or ‘signiﬁcant’ (>1 cm diameter or villous
histology) colorectal adenomas was identiﬁed from the
Adenoma Prevention with Celecoxib Trial.
All DNA was extracted from whole peripheral blood. Single
nucleotide polymorphism (SNP) genotyping, quality control and
imputation were performed according to standard procedures
outlined in the supplementary material, available online only. All
studies were performed in accordance with local research ethics
committee approval (Southampton and South-West Hampshire
REC (A) 06/Q1702/99).
Telomere assays and quality control
Telomere length was measured using minor modiﬁcations of
Cawthon’s monochrome multiplex quantitative PCR method
(details in Cawthon),32 which we found to provide far greater
consistency than other previously published methods; 98
samples were assayed in duplicate and for 93 of these, the
telomere length measurement lay within 15% of each other and
only two lay outside 25%. All samples were analysed by study of
origin in 96-well plate format together with ﬁve control dilu-
tions of a single, anonymous standard DNA, which was used to
ﬁt linear regression lines for the log(telomere) and log(HBG
control) Ct values and DNA concentration for each plate. Very
good ﬁts were observed (see supplementary ﬁgure 1, available
online only). For each sample on that plate, the Ct value for the
control probe was used to determine the amount of DNA in the
reaction from the standard line. From this value, the expected Ct
for the telomere was determined. The expected telomere Ct
value was then subtracted from that observed for that sample
according to the standard line, to give a relative telomere
measurement (CorrDCt) for each sample on each plate. In
summary, CorrDCt was the measured telomere length for each
sample relative to that of the anonymous standard sample; the
larger CorrDCt, the greater was the measured telomere length.
Assessment of functional effects of TERC variant
HCT116 CRC cells, a near-diploid line homozygous for the A
allele at rs2293607, were used in this experiment. TERC
messenger RNA was PCR-ampliﬁed using primers
TCCCTTTATAAGCCGACTC and ATTCATTTTGGCCGACTT,
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so as to encompass TERC transcripts AI825849 and AW207347.
This was cloned into pcDNA3.1 and clones of identical sequence,
apart from the A and G alleles at rs2293607, were obtained by
site-directed mutagenesis. HCT116 cells were transfected with
this construct using Lipofectamine 2000 under standard condi-
tions. Cells were co-transfected with pEGFP-C3 so as to measure
transfection efﬁciency using GFP expression. This conﬁrmed high
(>90%) efﬁciency in all cases. Cells transfected with empty
pcDNA3.1 and pEGFPc3 were used as controls. Based on pilot
experiments that estimated the time of maximum TERC
expression, we measured telomere lengths after 48 h. At the same
time, we measured total TERC expression using Taqman real-
time quantitative assay Hs03297287_s1 (Applied Biosystems),
with SF3B1 expression as a control. All experiments were
performed in triplicate.
RESULTS
Search for polymorphisms associated with telomere length in
leucocytes: confirmation of SNP near TERC but not TERT
Using a candidate locus approach, we identiﬁed from public
databases all SNP within 50 kb of a panel of genes proposed by
Mirabello et al33 as ‘telomere biology ’ candidates (see supple-
mentary table 2, available online only). One hundred and
twenty-eight tagging SNP in these regions (see supplementary
table 3, available online only) had been genotyped in our cases
and controls in all samples. We used real-time quantitative PCR
to determine the normalised telomere length in cases and
controls from each of the following sample sets (CORGI, COGS,
NBS, VICTOR). Data were stratiﬁed by case/control status,
sample set, age and sex. Using a threshold for association of
p¼104, approximating to a false discovery rate of 0.01, we
found ﬁve SNP (rs16854453, rs10936599, rs11709840, rs1920116,
rs10936603) to be associated with telomere length (table 1).
These SNP were all within a region of approximately 90 kb on
chromosome 3q26.2 (170,974,795e171,062,665 bases), were in
strong or moderate pairwise linkage disequilibrium (LD) (see
supplementary ﬁgure 2, available online only), and lay within
a haplotype block that encompassed the TERC locus (chr3:
170965092e170965542). We found that they were in strong LD
with a SNP (rs12696304) proximal to TERC that had previously
been reported to be associated with telomere length.13
No other ‘telomere biology ’ SNP was associated with telo-
mere length, the strongest association (p¼2.03103) being at
a SNP, rs27061, distal to TERT. The failure to ﬁnd an association
between TERT SNP and telomere length conﬁrms the data of
other groups13 34 and is of note, because SNP at this site
(rs401681, rs4635969, rs2736100, rs4975616, rs2736098) have
previously been associated with cancer risk35; each of these ﬁve
SNP or a proxy (r2w1.0) was typed in our samples.
TERC SNP are associated with increased risk of CRC
At the same time as our study of telomere length in CRC
patients, we were undertaking a genome-wide association study
of CRC. The latest stage of the genome-wide association study
based on 11 caseecontrol cohorts,31 including several that
sampled incident cases, found that rs10936599 showed a signif-
icant association with CRC risk (p¼2.553108, ORper allele 0.93,
95% CI 0.91 to 0.96), independent of age and sex. Table 2 shows
rs10936599 genotype counts in the sample sets used in this
study. As rs10936599 is a synonymous SNP within an exon of
myoneurin (MYNN), we had reported MYNN as the gene close
to rs10936599 most likely to harbour functional variation.31
However, our ﬁnding that rs10936599 was associated with
telomere length prompted a more detailed investigation. We
initially conﬁrmed that, although the other four TERC SNP
associated with telomere length were not genotyped in all 11
caseecontrol cohorts, each showed evidence of association with
CRC risk (see supplementary table 4, available online only). As
the major allele at rs10936599 was associated with both longer
telomeres and CRC risk, the genetic analysis strongly suggested
that, if leucocyte telomeres are a valid proxy for those in colo-
nocytes, longer telomeres were associated with an increased risk
of CRC.
rs10936599 Genotype is associated with risk of colorectal
adenomas
Telomerase activity has generally been associated with carci-
nomas rather than their benign precursors. However, we
wondered whether the effect of rs10936599 might also be
mediated in normal tissue or in early tumorigenesis (eg, by
effects in normal stem cells). We therefore examined whether
rs10936599 alleles were associated with disease in patients with
colorectal adenomas who had not developed CRC. Cases were
derived from the Adenoma Prevention with Celecoxib adenoma
prevention trial;36 controls were from the publicly available 1958
UK Birth Cohort.37 After stratifying for a family history of CRC,
the major allele at rs10936599 was associated with an increased
risk of adenomas (table 2; OR 0.883, 95% CI 0.80 to 0.98;
c21¼5.30, p¼0.011). The variation close to TERC thus probably
acts, at least partly, at an early stage in tumorigenesis.
Evidence that the variation tagged by rs10936599 acts through
telomere length
Although we thought it highly plausible that rs10936599 alleles
affected CRC risk through telomere length, it was possible that
the functional variation associated with rs10936599 acted
through another mechanism and that the association with
telomere length was an epiphenomenon. Given the potential
confounding effect on telomere length of patients having CRC
or receiving treatment for their disease26 and in the absence of
prospective cohort data, we could not test this alternative
hypothesis by directly examining rs10936599 genotypes and
telomere lengths in our CRC cases and controls. We therefore
undertook an indirect test. Assuming that telomere length in
leucocytes is a proxy for that in colonocytes, we reasoned the
following: if the inﬂuence of rs10936599 genotype on CRC risk
Table 1 SNP associated with telomere length
SNP Chr Position N p Value p (R) Beta Beta (R) Q I2
rs16854453 3 171041936 4 3.383106 4.863105 0.067 0.066 0.321 14.3
rs10936599 3 170974803 5 3.923105 3.923105 0.055 0.055 0.580 0.0
rs11709840 3 171052943 4 4.143105 4.143105 0.059 0.059 0.528 0.0
rs1920116 3 171062673 5 4.193105 4.193105 0.055 0.055 0.612 0.0
rs10936603 3 171028354 5 4.533105 7.393104 0.055 0.053 0.288 19.9
Beta, ln(OR); Chr, chromosome; I2, test of heterogeneity; Position, single nucleotide polymorphism (SNP) location in base pairs in NCBI genome Build 36; p (R), fixed effects p value in linear
regression meta-analysis; p Value, fixed effects p value in linear regression meta-analysis; Q,Cochran’s Q statistic.
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is not mediated through telomere length, the effect size of
rs10936599 should not vary with telomere length; any variation
in the effect size of rs10936599 with telomere length would be
most likely to result from a direct effect of longer telomeres on
CRC risk, for example, by pushing those with generally long
telomeres over some threshold at which cancer risk was partic-
ularly increased. In order to standardise telomere lengths among
the case sample sets (CORGI, VICTOR, COGS), we ranked each
individual according to the length of their telomeres in that
sample set. We then used logistic regression analysis to deter-
mine the effect size of rs10936599 according to the rank of the
individuals in each case data set compared with all controls,
stratifying by sex, age and study of origin. We initially observed
that when cases with relatively short telomeres (ie, in the ﬁrst
and/or second quartiles) were studied, the effect of the
rs10936599 genotype was not signiﬁcant, whereas a signiﬁcant
effect was seen in the third quartile and a highly signiﬁcant
effect (ln(OR) 0.43, p¼5.043108) was seen in the fourth
quartile. More generally, we tested whether rs10936599 effect
size was related to ranked telomere length by regressing ln(OR)
on telomere decile; a signiﬁcant linear relationship was found (ln
(OR) (0.04183decile) +0.0561; R2¼0.5882; t¼3.38, p¼0.010;
see supplementary ﬁgure 3, available online only). While the
underlying origin of this association is unclear, its existence
suggests that rs10936599 directly affects CRC risk through
telomere length.
Annotation and fine mapping of the 3q26.2 region
From HapMap two data (http://www.hapmap.org/), we found
that rs10936599 (chr3: 170,974,795) is in strong or moderate LD
with SNP within the region chr3: 170,941,263e171,012,592 that
includes the genes TERC, ARPM1, MYNN and LRRC34. Using
1000genomes project data (http://www.1000genomes.org/), 44
SNP within this region were found to be correlated with
rs10936599 with r2>0.5 (see supplementary table 5, available
online only).
The only SNP fulﬁlling these LD criteria that was both within
or close to TERC and had promising functional annotation was
rs2293607 (chr3: 170,965,029; r2¼1.0 with rs10936599, http://
www.biomart.org/). The most abundant TERC transcript maps
to chr3: 170,965,092e170,965,542, but two other TERC tran-
scripts contain rs2293607 (AI825849, chr3: 170,965,004e
170,965,446 and AW207347, chr3: 170,965,002e170,965,373).
rs2293607 was predicted by RNAfold (http://rna.tbi.univie.ac.at/
cgi-bin/RNAfold.cgi) to alter the transcript’s secondary mRNA
structure (see supplementary ﬁgure 4, available online only).
Moreover, data from the ENCODE project (http://genome.ucsc.
edu/cgi-in/hgTrackUi?hgsid¼174313571&c¼chr15&g¼wgEnco-
deReg) indicated two histone marks (H3K4Me1 and H3K4Me3)
in the immediate vicinity of rs2293607. The same region was also
DNaseI-hypersensitive and the predicted binding site of multiple
transcription factors, including NFKB, PU.1, POU2F2 and MYC
(http://genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid¼174313571&
c¼chr15&g¼wgEncodeReg).
In order to reﬁne the location of the causal variation in the
region around TERC, we inspected association signals between
SNP genotype and telomere length and CRC susceptibility,
following imputation of SNP using the 1000genomes project as
a reference. In general, the association plots for the two variables
mirrored each other (see supplementary ﬁgure 5, available online
only), and consequently the effect sizes were very strongly
correlated (t¼27.6, p<0.001). In both cases, the strongest signal
was found at approximately 171.05 Mb, although the associa-
tions at that site were only marginally stronger than those
present in a larger region that included rs2293607 between
approximately 170.90 Mb and 171.05 Mb.
In-vitro analysis of the effects of rs2293607 genotypes in TERC
transcripts
As a result of the possible effects of rs2293607 on TERC RNA
structure or transcription, we performed functional assays on
TERC transcripts that varied only at the A (major, CRC risk,
longer telomere) and G (minor, CRC protection, shorter telo-
mere) alleles at this site. In order to examine effects in cells of
large bowel origin, we used the CRC cell line HCT116 as
a model system. We expressed exogenous TERC transcripts that
varied only at the A/G polymorphic site, performing each
experiment in triplicate and controlling for potential differences
in transfection efﬁciency between experiments. Initially, we
quantiﬁed the expression of total (endogenous and exogenous)
TERC mRNA for each of the two variants in comparison with
empty vector and untransfected controls. We found that after
48 h, total TERC expression was higher in cells expressing the
exogenous TERC, and that cells with the A allele construct
expressed higher TERC than those with the G allele (ﬁgure 1).
We then examined whether the increased TERC expression
associated with the A allele had functional consequences.
Although no gross differences in HCT116 morphology or
behaviour were observed at the 48 h time point, we did not
necessarily expect these in a transformed cell line. We therefore
assayed telomere length in cells with the A and G allele tran-
scripts. This showed that, in concordance with our hypothesis,
expression of the A allele TERC transcript resulted in longer
telomeres in HCT116, whereas the G allele had little effect on
telomeres compared with the control cells (ﬁgure 1).
Telomere length in CRC cases versus controls
Given the prediction from our work above that CRC risk is
associated with longer telomeres, yet pre-existing evidence
suggests that CRC cases have shorter telomeres than controls,26
we compared telomere length in our three sets of CRC cases
(VICTOR, CORGI and COGS) and in the three sets of controls
(CORGI, COGS and NBS). Telomere length (CorrDCt) was
approximately normally distributed (see supplementary ﬁgure 6,
Table 2 Risk of CRC and colorectal adenoma associated with the rs10936599 SNP
Series Ca11 Ca12 Ca22 Co11 Co12 Co22 MAF ca MAF co OR
VQ58 69 413 731 150 932 1407 0.23 0.25 0.894
UK1/CORGI 30 162 360 25 162 268 0.20 0.23 0.829
Scotland1/COGS 50 301 537 69 383 516 0.23 0.27 0.792
APC adenomas/NBS 75 558 936 152 936 1412 0.23 0.25 0.883
Genotype counts in cases (Ca) and controls (Co) are shown by sample series.
Allele 1¼A, Allele 2¼G.
Meta-analysis of the three colorectal cancer (CRC) caseecontrol series gives OR 0.85 (95% CI 0.78 to 0.93), p¼1.573104, phet¼0.442.
Note that only the data from the sample sets in this study are shown; the full genome-wide association study data can be obtained from Jeanclos et al.31
APC, Adenoma Prevention with Celecoxib Trial; MAF, minor allele frequency; NBS, National Blood Service; SNP, single nucleotide polymorphism.
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available online only) and decreased with age (see supplemen-
tary ﬁgure 7, available online only). Incorporating age, sex and
study of origin as covariates, we performed logistic regression
analysis to compare case and control telomere lengths. We used
NBS controls as a comparison with VICTOR because of the
absence of unaffected controls from the clinical trial sample set.
Contrary to expectations from our genetic data, but consistent
with previous retrospective studies, we found that cases had
signiﬁcantly shorter telomeres than controls (mean CorrDctcases
1.04, mean CorrDCtcontrols 1.11), although there was also
considerable variation between sample series (ﬁgure 2). Overall,
after stratifying for age, sex, sample set and rs10936599 geno-
type, telomeres were signiﬁcantly shorter in cases than controls
(OR 0.71, 95% CI 0.56 to 0.90, z¼2.85, p¼4.373103).
The CORGI and VICTOR study cases were collected months,
or occasionally years, after diagnosis and treatment. We there-
fore compared telomere lengths in these two sets of cases with
those in the COGS cases, which were collected closer to diag-
nosis. After controlling for age, sex and rs10936599 genotype,
the COGS samples had signiﬁcantly longer telomeres than the
other samples (p¼4.223106, logistic regression analysis). We
then explored possible causes for this ﬁnding. We used multiple
linear regression to search within VICTORdas this was a high-
quality clinical trial dataset with full clinical and follow-up
datadfor associations between telomere length and the
following: (1) use of chemotherapy (all 5-ﬂuorouracil-based) or
rofecoxib; (2) use of radiotherapy; (3) blood sampling time after
surgery and (4) CRC stage. After controlling for age and sex, we
found no association between telomere length and chemo-
therapy (p¼0.88), rofecoxib (p¼0.87), radiotherapy (p¼0.053),
sampling time (p¼0.18) or stage (p¼0.42). There was, moreover,
no association between recurrence-free survival and telomere
length (HR 0.94, p¼0.87, Cox proportional hazards model) after
correcting for stage, radiotherapy, chemotherapy, age and sex
(details not shown).
DISCUSSION
We have conﬁrmed that SNP close to the TERC locus are asso-
ciated with leucocyte telomere length in humans, using methods
that were different from those in the previous studies of Codd
et al13 and Levy et al.14 We also found independently that the
same TERC SNP are associated with susceptibility to CRC.
However, the SNP data show that, contrary to expectations,
individuals with longer telomeres are predicted to be at increased
risk of CRC.
The causal variation close to TERC and its mode of action
remain to be identiﬁed, although it is most likely to lie within
the region 170.90 Mbe171.05 Mb. We investigated the candi-
date SNP rs2293607 as a result of its genetic association with
rs10936599 and rs12696304, together with its predicted effects
on mRNA structure and/or expression. Our evidence suggests
that rs2293607 might indeed have functional effects on TERC
expression and thus on telomere length. If increased CRC risk
does directly result from long telomeres, one plausible model is
that telomere lengthening increases a normal cell’s stem-like
properties and thus its chances of acquiring tumour-causing
mutations, consistent with the increased risk of both adenomas
and carcinomas associated with rs10936599.
Figure 1 Telomerase RNA component expression (A) and telomere length (B) in HCT116 after transfection with telomerase RNA component
constructs carrying the A and G alleles at rs2293607, compared with empty vector and untransfected cells. Error bars show SEM of experiments
performed in triplicate.
Figure 2 Telomere lengths in cases and controls from each sample
set. The bar chart shows mean CorrDCt for each sample set (error bars
show standard deviations). Note the shorter telomeres in cases than
controls, with the exception of the COGS cases, which have similar
lengths to the some other control sample sets, although shorter lengths
than their corresponding controls.
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Despite the genetic evidence predicting that longer telomeres
increase CRC risk, evidence from retrospective studies, such as
our own, has shown that telomeres in peripheral blood cells are
shorter in CRC cases than controls. However, associations
between telomere length and CRC risk have not been shown in
prospective studies, despite such studies probably including
individuals with occult cancers. Although the prospective
studies may have been too small to detect associations between
telomere length and cancer reliably, the data as a whole suggest
that the association between short telomeres and CRC in
retrospective studies is in some way the result of disease or
differential survival rather than the cause. Our samples taken
closer to diagnosis (COGS study) had longer telomeres than
those taken months or years after diagnosis (CORGI or
VICTOR). These data are consistent with an association
between longer telomeres and poorer survival, or with telomere
attrition in the aftermath of treatment. However, our three sets
of CRC cases differed in several ways other than sampling time,
such as the therapeutic regimens used, inclusion criteria and
ethnicity. We therefore also searched for evidence that telomere
length depended on time between surgery and sampling or
recurrence-free survival in VICTOR, because it was a clinical
trial with excellent follow-up data. However, we found no
association in either case. We also found no evidence that
5-ﬂuorouracil-based chemotherapy or radiotherapy was associ-
ated with shorter telomeres in VICTOR. Given the long time
between surgery and sampling in VICTOR and consequent
sampling bias against early recurrence, we suggest that
a requirement is an analysis of telomere length and survival
based on a set of CRC cases sampled close to diagnosis, ideally
before chemotherapy, and with excellent follow-up data.
The rival models linking telomere length and colorectal
tumorigenesis are shown in ﬁgure 3. However, several further
issues remain regarding telomeres, TERC and CRC risk.
1. Telomerase may repair DNA other than at telomeres,38e40
because de novo synthesis of telomere repeats may occur at
double-stranded breaks. Despite our evidence to the contrary,
it may be these extra-telomeric functions that are causally
associated with increased CRC risk.
2. Telomere length is most conveniently measured in peripheral
blood: this can lead to non-genetic variation between samples
(eg, if the composition of the leucocyte count varies) and it
may not reﬂect the situation in the target tissue for cancer
development. In particular, we believe it most unlikely that
circulating DNA shed from cancer cells that have short
telomeres contributed anything other than a tiny proportion
of the total blood DNA inwhich wemeasured telomere length
in CRC cases. We attempted to minimise sampling issues by
collecting in a similar fashion from cases and controls when
possible (notably in CORGI and COGS). However, this had
to be balanced against the practicalities of empowering the
study with enough samples (eg, we used NBS controls as
a comparison with VICTOR as a result of the absence of
unaffected controls from those clinical trial sample sets). Data
were analysed throughout having stratiﬁed by sample set.
3. There was overlap between the NBS samples analysed both
in this study and that of Codd et al.13 However, even
excluding these samples, the association between rs10936599
and telomere length remained (OR 0.673, 95% CI 0.511 to
0.886, p¼53103). In fact, the consistency between our work
and that of Codd et al13 provides good evidence of the
technical validity of our assays.32
4. It is possible that the association between telomere length
and cancer risk is non-montonic, allowing shorter telomeres
to be associated with CRC overall, yet the minor TERC allele
to be protective.
5. It is a further conundrum that TERT tagSNP have been
reported to be associated with an increased risks of lung,
Figure 3 Models of associations
between telomere length and colorectal
cancer (CRC) risk. Arrows indicate
causality. (1) The current model is
based on observation of shorter
leucocytes telomeres in CRC cases than
controls, assumes that this is mirrored
in colorectal crypt stem cells and posits
a causal link between shorter telomeres
and CRC development, possibly through
chromosomal instability. (2) Our model
proposes that genetic factors cause
longer telomeres, assumes that this is
mirrored in colorectal crypt stem cells
and proposes that longer telomeres
directly influences CRC risk, possibly
through effects on stem cell numbers or
longevity. The shorter telomeres in
retrospectively collected CRC arise as
a result of disease or as a sample
collection artefact caused by shorter
survival in individuals with longer
telomeres. (3) A third possibility must
be borne in mind, namely that genetic
factors cause longer telomeres, but that
the genetic factors do not influence risk
through telomere length, which is an
epiphenomenon with no relevance or
even a partially compensatory restraining
influence on carcinogenesis; shorter telomeres
of other origins may still cause an increased CRC risk.
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breast and other cancers, yet common genetic variants at
TERT are not associated with telomere length in the studies
undertaken to date. The reason underlying the organ or
site-speciﬁc associations of cancers with TERC or TERT
polymorphisms remains unclear.
Telomere length is a trait that is highly likely to be under
stabilising selection. If telomeres are too short, they predispose
to chromosomal aberrations and the diseases that result.
However, they may also lead to earlier cell death, especially if
DNA damage checkpoints are active. Very long-lived humans
tend to have long telomeres, so what is the downside of having
very long telomeres? Our work suggests that at least part of this
downside is increased CRC risk, and there is evidence to support
this contention in that chronically increased TERT expression
promotes tumorigenesis in mouse models.41 Although some of
the data are paradoxical, there is a clear link between rs10936599
and longer telomeres in leucocytes and increased risk of CRC.
This ﬁnding may overcome some of the problems inherent in
directly measuring telomere length in retrospectively collected
cancer cases and controls. We propose that the previously
reported associations between cancer risk and short telomeres in
the general population wrongly emphasised the chromosomal
instability aspects of cancer risk over the aspects relating to cell
lifespan and stem-like properties.
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